Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase II Trial of Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With no Squamous Non Small Cell Lung Cancer Refractory to First Line Chemotherapy

NCT02531737 is registered in ClinicalTrials.gov with University Hospital, Limoges as lead sponsor.

NCT NCT02531737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02531737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase II Trial of Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With no Squamous Non Small Cell Lung Cancer Refractory to First Line Chemotherapy
Lead sponsor
University Hospital, Limoges
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
September 26, 2020
Enrollment
59 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasms